5-Hydroxytryptophan / Risk Cancer Research Results

5-HTP, 5-Hydroxytryptophan: Click to Expand ⟱
Features:
5-HTP (5-Hydroxytryptophan) is a naturally occurring amino acid and chemical precursor in the biosynthesis of serotonin(5-HT).

5-HTP — 5-Hydroxytryptophan (L-5-HTP) is an endogenous amino-acid intermediate in tryptophan metabolism and the immediate biochemical precursor to serotonin (5-HT) and downstream melatonin. It is most commonly used as an orally administered dietary supplement (often derived from Griffonia simplicifolia seed extracts) rather than as a regulated drug product; common abbreviations include 5-HTP and L-5-HTP. In humans it is rapidly converted by aromatic L-amino-acid decarboxylase (AADC/DDC) to serotonin largely in peripheral tissues unless peripheral decarboxylation is pharmacologically inhibited.

Primary mechanisms (ranked):

  1. ↑ Serotonin biosynthesis via AADC/DDC conversion of 5-HTP to 5-HT (rate-limited by peripheral decarboxylation and transport into the CNS)
  2. ↑ Melatonin biosynthesis (indirect) by increasing serotonin substrate availability in pineal pathways (context-dependent)
  3. ↑/↔ Serotonergic GPCR signaling downstream of increased 5-HT tone (5-HT receptor subtype–dependent; includes cAMP/PKA and PLC/IP3/Ca²⁺ axes)
  4. ↔ Platelet and vascular serotonergic tone (serotonin uptake/release; hemostasis/vasoreactivity; context-dependent)
  5. Secondary redox modulation via (a) melatonin’s antioxidant signaling and (b) MAO-dependent 5-HT metabolism generating H₂O₂ (context-dependent)

Bioavailability / PK relevance: Oral PK is variable with prominent peripheral conversion to serotonin; historical human PK work reports multi-hour half-life and non-linear/variable exposure, with substantially altered disposition when co-administered with peripheral decarboxylase inhibitors (e.g., carbidopa) which reduces peripheral conversion and can increase CNS availability.

In-vitro vs systemic exposure relevance: Most mechanistic cellular studies that dose supraphysiologic 5-HTP/5-HT concentrations may exceed achievable free systemic levels with typical supplement dosing; many downstream effects are better interpreted as serotonergic tone (receptor-mediated) rather than direct intracellular target engagement by 5-HTP.

Clinical evidence status: Small-human evidence exists primarily in non-oncology indications (e.g., depression) but is limited by study quality/size; there is no credible clinical anticancer evidence base. Safety constraints and interaction risk (serotonergic drugs) are clinically material and often dominate translation decisions.

5-HTP (AD context) — In Alzheimer’s disease (AD), 5-HTP is mechanistically relevant only indirectly: it can increase serotonin availability (limited by peripheral decarboxylation) and may secondarily influence sleep/circadian biology via serotonin→melatonin pathways. The human evidence for 5-HTP in AD specifically is not established; available clinical work is better described as small studies in older adults (not necessarily AD) assessing cognition/mood, while broader AD-relevant biology is supported mainly by serotonergic-system and melatonin literature rather than 5-HTP intervention trials.

Primary mechanisms (ranked):

  1. ↑/↔ Central serotonergic tone (limited/variable CNS delivery; receptor subtype–dependent)
  2. ↑ Sleep/circadian support via serotonin→melatonin substrate effects (context-dependent)
  3. ↓/↔ Oxidative stress and mitochondrial stress (secondary; largely via melatonin-linked pathways; context-dependent)
  4. ↔ Neuroinflammation and synaptic function (secondary; downstream of serotonergic receptor signaling; context-dependent)
-Serotonin (from 5-HTP) is further converted into melatonin in the pineal gland, regulating sleep-wake cycles
- 5-HTP freely crosses the blood–brain barrier.
-Serotonin Does not cross the blood-brain barrier well if excessively converted in the periphery, which is why it's often taken with carbidopa (a peripheral decarboxylase inhibitor) in clinical contexts.
-Doses over ~300–400 mg/day should be taken cautiously and under supervision.
-Alzheimer’s Disease (AD) patients show marked reductions in serotonin levels and serotonergic neurons, especially in the raphe nuclei and hippocampus. 5-HTP could help restore serotonin levels in the brain, potentially supporting cognition and mood.
-5-HTP may help reduce microglial activation and inflammatory cytokines (e.g. TNF-α, IL-6), both elevated in AD.
-Serotonin and melatonin (a downstream product of 5-HTP) have antioxidant properties, which might help reduce ROS-induced neuronal damage in AD.
-Many AD patients are on SSRIs or cholinesterase inhibitors, which could interact with 5-HTP.

Alzheimer’s-relevant axes for 5-HTP (indirect)

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Central serotonergic function ↑/↔ (delivery-dependent) P/R Potential symptom-domain effects (mood, sleep, behavior) AD biology includes serotonergic-system alterations; 5-HTP’s ability to shift CNS serotonin is variable due to peripheral decarboxylation and competing transport/handling.
2 Sleep–circadian axis ↑/↔ (context-dependent) R/G Sleep consolidation and circadian support Melatonin disruption is common in AD; 5-HTP may increase serotonin substrate for melatonin synthesis in some contexts, but this is indirect and not reliably demonstrated as an AD intervention.
3 Mitochondria and oxidative stress ↓/↔ (secondary) R/G Redox/mitochondrial stress buffering Mechanistic support is stronger for melatonin itself in neurodegeneration than for 5-HTP as a means to raise melatonin in AD.
4 Neuroinflammation and synaptic plasticity ↔ (secondary) G Downstream signaling shifts Serotonergic receptor signaling can modulate inflammatory tone and synaptic function, but directionality is receptor- and circuit-dependent; not a specific 5-HTP signature.
5 Clinical Translation Constraint — — Evidence gap + interaction + quality control No AD-specific efficacy base; serotonergic drug interactions matter in older adults; product quality/impurity concerns have been reported historically in some commercial 5-HTP lots.


Risk, Risk: Click to Expand ⟱
Source:
Type:
Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive. 
Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral




CRIS Exposure / Compound Evidence Cancers Notes




-5 Exercise (overall)
VStrong Hum BC, CRC, Endo, PCa, Liv






-5 Aerobic + resistance VStrong Hum Broad inc + mort






-4 Aerobic exercise (mod–vig) VStrong Hum BC, CRC, Endo






-4 Resistance training (alone) Strong Hum BC, CRC






-3 High-intensity interval training Mod–Strong Hum BC, CRC






-2 NEAT / low-intensity activity Moderate Hum CRC






-5 Cruciferous vegetable pattern Strong Hum Lung, CRC, BC, PCa






-5 Sunlight exposure (physiologic) Strong Hum CRC, BC, PCa






-4 Fasting (metabolic pattern)
Strong Mech + Hum BC, CRC, PCa 






-4 Curcumin
Hum + Pre GI, BC, PCa






-4 Sulforaphane
Hum + Pre Lung, CRC, BC






-4 PEITC
Hum + Pre Lung, CRC, PCa






-4 EGCG (tea matrix)
Strong Hum GI, PCa, BC






-4 Lycopene
Strong Hum PCa






-4 Apigenin
Pre + Diet Hum BC, PCa, CRC 






-4 Luteolin
Pre + Diet Hum Lung, CRC, BC 






-4 Kaempferol
Diet Hum Ov, Panc, Lung






-4 Fisetin
Pre + Early Hum CRC, PCa, Mel






-4 Ellagic acid → Urolithin A
Hum (microbiome) CRC, PCa, BC






-3 Omega-3 (EPA/DHA)
Strong Hum CRC, BC






-3 Vitamin D3 (supp)
Obs + RCT CRC, BC






-3 Garlic (allicin)
Mod Hum GI






-3 Mushroom beta-glucans
Hum adjunct GI, BC






-3 Melatonin
Hum + Mech BC, PCa






-3 Coffee (whole)
Strong Hum Liv, Endo






-2 Quercetin
Limited Hum Lung, CRC






-2 Resveratrol
Limited Hum CRC, BC






-2 I3C / DIM
Mod Hum BC, Cerv






-2 Thymoquinone
Early Hum BC, CRC






-2 Beta-carotene (food)
Hum Lung






-1 Vitamin K2 (MK-4/7)
Limited Hum Liv, PCa






-1 Boron
Obs PCa, Lung






0 Vitamin C (oral)
Strong Hum —






0 Genistein (soy)
Strong Hum BC, PCa






0 Selenium (diet)
Mixed Hum PCa






0 Capsaicin
Mixed Gastric






+2 Vitamin E (alpha only)
Strong RCT PCa






+2 Green tea extract (high-dose)
Case reports Liv






+4 Beta-carotene (supplement)
Strong RCT Lung (smokers)






+5 Alcohol (ethanol)
Strong Hum BC, Liv, Eso







Evidence
Hum        human data
VStrong    very strong
Strong     strong
Mod        moderate
Obs        observational
Pre        preclinical
RCT        randomized controlled trial
Mech       mechanistic
Adjunct    adjunct clinical use


Scientific Papers found: Click to Expand⟱
5304- 5-HTP,    Serotoninergic System in Dementia of the Alzheimer Type
- Human, AD, NA
*Risk↓,
5296- 5-HTP,    Serotonergic Regulation in Alzheimer’s Disease
- Review, AD, NA
*Risk↓, *5HT↓, *ROS↓, *MDA↓, *Apoptosis↓, *Mood↑, *other↑, *other↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

MDA↓, 1,   ROS↓, 1,  

Cell Death ⓘ

Apoptosis↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 2,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Functional Outcomes ⓘ

Mood↑, 1,   Risk↓, 2,  
Total Targets: 7

Scientific Paper Hit Count for: Risk, Risk
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:152  Target#:785  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page